ADJUnct Semaglutide Treatment in Type 1 Diabetes

Phase 2 Completed 115 enrolled Viral N. Shah Juvenile Diabetes Research Foundation · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to assess the use of once weekly semaglutide injection in inadequately controlled obese adults with type 1 diabetes (T1D) using FDA-approved hybrid closed-loop therapies.

Timeline

Start: 2023-04-11
Primary completion: 2024-08-06
Completion: 2024-08-06

Outcome

Met primary endpoint

paper A significantly greater percentage of patients in the semaglutide group than in the placebo group achieved the primary composite outcome PMID 40550013 ↗

paper primary composite outcome (36% vs. 0%; between-group difference, 36 percentage points; 95% confidence interval [CI], 20.6 to 52.2; P<0.001). PMID 40550013 ↗

Publications

Shah VN, Akturk HK, Kruger D, Ahmann A, Bhargava A, Bakoyannis G, Pyle L, Snell-Bergeon JK. Semaglutide in Adults with Type 1 Diabetes and Obesity. NEJM Evid. 2025 Aug;4(8):EVIDoa2500173. doi: 10.1056/EVIDoa2500173. Epub 2025 Jun 23.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Semaglutide	Peptide	1 mg	Other